Published in Hospital Business Week, February 4th, 2007
According to recent research from the United States, "Platinum-based doublets are recommended as treatment for advanced or metastatic NSCLC; however, chemotherapy must be tailored to limit side effects. A phase II study was conducted to evaluate the efficacy and safety of oxaliplatin combined with docetaxel for NSCLC. Patients with stage IIIB or IV, chemotherapy-naive NSCLC received docetaxel 70 mg/m2, oxaliplatin 130...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Hospital Business Week
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.